Pheochromocytoma - Pipeline Insight, 2019 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pheochromocytoma pipeline landscape is provided which includes the disease overview and Pheochromocytoma treatment guidelines. The assessment part of the report embraces, in depth Pheochromocytoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pheochromocytoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Pheochromocytoma is a rare, catecholamine-secreting tumor that may precipitate life-threatening hypertension. Pheochromocytomas grow within the center part of the adrenal gland termed the adrenal medulla and may occur as a single tumor or as more than one growth. The tumor is malignant in 10% of cases but may be cured completely by surgical removal. Pheochromocytoma has classically been associated with three syndromes—von Hippel-Lindau (VHL) syndrome, multiple endocrine neoplasia type 2 (MEN 2), and neurofibromatosis type 1 (NF1). Symptoms are usually episodic and tend to progress as the tumor grows. The majority of these tumors are benign. About 80% to 90% arise in the adrenal gland while the remaining being extra-adrenal in origin and most commonly found in the head and neck. These tumors mostly develop sporadically.
Pheochromocytoma Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Pheochromocytoma targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Pheochromocytoma pipeline report covers 11+ companies. Some of the key players include Exelixis (Cabozantinib) and Pfizer (Sunitinib), Advanced Accelerator Applications (Lutathera) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Pheochromocytoma Analytical Perspective by DelveInsight
• In-depth Pheochromocytoma Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Pheochromocytoma Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
• The Pheochromocytoma report provides an overview of therapeutic pipeline activity for Pheochromocytoma across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Pheochromocytoma therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Pheochromocytoma Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Pheochromocytoma
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Pheochromocytoma to formulate effective R&D strategies
• Assess challenges and opportunities that influence Pheochromocytoma R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Pheochromocytoma in licensing and out licensing strategies by identifying prospective partners with progressing projects for Pheochromocytoma to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs*Please Note:* The report will be delivered in 2 business days upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook